Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — FY2022 Earnings Presentation
14 slides from Zealand Pharma A/s's earnings presentation, Mar 2, 2023
Slide 1: FY 2022 Annual Report
FY 2022 Annual Report Zealand Pharma March 2, 2023
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharm
Slide 3: In 2022 we delivered on our strategic objectives and achieved significant pipeline progress
In 2022 we delivered on our strategic objectives and achieved significant pipeline progress Announced V-Go® sale strategy to to MannKind Corporate highlights prioritize R&D Zegalogue® partnership and restructure with Novo Nordisk ✓ Implemented operational commercial efficiencies & cost reductions op
Slide 4: In 2023 we have three key strategic objectives focused on maximizing the value potential of our pipeline
In 2023 we have three key strategic objectives focused on maximizing the value potential of our pipeline 1 Progress rare disease assets 2 3 Engage in strategic Advance obesity portfolio toward regulatory filings partnership discussions Dasiglucagon for congenital BI 4569062 (GCGR/GLP-1R) Rare diseas
Slide 5: Dasiglucagon has potential to address shortcomings of current management of CHI
Dasiglucagon has potential to address shortcomings of current management of CHI CHI is an ultra-rare disease in newborns and children • 1 in 28-50,000 newborns per year are diagnosed with genetically determined CHI in the US and EU1,2 • CHI can cause serious episodes of hypoglycemia during childhood
Slide 6: Opportunity to treat up to 800 patients with diffuse CHI at ultra-rare disease price levels
Opportunity to treat up to 800 patients with diffuse CHI at ultra-rare disease price levels in the US Patients eligible for dasiglucagon Ultra-rare disease therapy analogues with clear treatment in the US clinical value command premium prices in US5 Annual treatment cost (k$) Diffuse CHI patients 1.
Slide 7: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration , diseases Dasiglucagon: S.C. Continuous Infusion Congenital Hyperinsulinism Rare Glepaglutide (GLP-2 Analog) Short Bowel Syndrome BI 456906 (GCGR/GLP-1
Slide 8: Glepaglutide continues to be evaluated in Phase 3 long term extension studies in SBS
Glepaglutide continues to be evaluated in Phase 3 long term extension studies in SBS Phase 3a pivotal trial EASE 1 Placebo, once and twice NCT03690206 weekly treatment (~24 weeks) • 102 of 106 patients completed EASE 1 • 96 patients continued into the ongoing safety and efficacy extension trials Pha
Slide 9: Obesity is a complex metabolic disease requiring additional treatment options
Obesity is a complex metabolic disease requiring additional treatment options 650 million adults and 124 million children and adolescents suffering from obesity1 Dual-pharmacology holds great promise Zealand Pharma’s peptide approach in treatment of obesity % Dual agonists (one molecule – two action
Slide 10: Targeting obesity with differentiated candidates
Targeting obesity with differentiated candidates Dual pharmacology with a GLP-1 Single pharmacology as receptor agonist foundation combinable alternative modality GLP-1 Designed for administering • Increase insulin sensitivity as a “loose combination” • Delay gastric emptying or co-formulation with
Slide 11: Profit & Loss
Profit & Loss DKK million 2022 2021 P&L reflecting Zealand’s ambition to be leading peptide drug discovery and development company while commercializing products through partnerships Revenue 104.0 108.5 • Revenue of DKK 104 million in 2022 driven by development agreement with Gross margin 104.0 97.6
Slide 12: Strong cash position allows for investments in R&D
Strong cash position allows for investments in R&D DKK million Cash position of DKK 1,178 million 1.428 1.500 1.178 1,178 842 1.000 1.061 500 469 0 Cash position Cash invested1 Oberland Gross proceeds Cash position 2018 2019 2020 2021 2022 year-end 2021 year-end 2022 Securities Cash & cash equivalen
Slide 13: 2023 financial guidance
2023 financial guidance DKK million 2023 2022 Guidance Actual Revenue anticipated from existing and new license and No guidance 104 partnership agreements due to uncertain size and timing Net operating expenses1 800 - 900 941 Notes 1. Net operating expenses consist of R&D, S&M, G&A and other operati
Slide 14: Q&A session
Q&A session• 1H 2022 presentation 11 August 2022 14